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Abstract  27 
Biotin is an archetypal vitamin used as cofactor for carboxylation reactions found in all forms of 28 
life. However, biotin biosynthesis is an elaborate multi-enzymatic process and metabolically 29 
costly. Moreover, many industrially relevant organisms are incapable of biotin synthesis 30 
resulting in the requirement to supplement defined media. Here we describe the creation of 31 
biotin-independent strains of Escherichia coli and Corynebacterium glutamicum through 32 
installation of an optimized malonyl-CoA bypass, which re-routes natural fatty acid synthesis, 33 
rendering the previously essential vitamin completely obsolete. We utilize biotin-independent 34 
E. coli for the production of the high-value protein streptavidin which was hitherto restricted 35 
because of toxic effects due to biotin depletion. The engineered strain revealed significantly 36 
improved streptavidin production resulting in the highest titers and productivities reported for 37 
this protein to date. 38 
 39 
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 51 
1. Introduction  52 
Vitamins play an important role as cofactors in enzymes and fulfill a multitude of other essential 53 
biological functions including signaling, regulation, electron transfer, oxidation protection and 54 
radical scavenging1. Correspondingly, vitamin deprivation or inadequate intake cause severe 55 
metabolic disorders such as cardiovascular disease, increased risk for cancer and miscarriage, 56 
and osteoporosis to name but a few2. Biotin (or vitamin B7/H) constitutes an archetypal 57 
representative for vitamins since it is inevitably required by most independently living organisms 58 
distributed over the three domains of life1 with some exceptions in archaeal clades3. While only 59 
synthesized by some bacteria, yeasts, molds, algae and plants, mammals rely on dietary uptake of 60 
the vitamin or its supply from the intestinal microflora1,4. Biotin serves as enzymatic cofactor in 61 
carboxylation reactions in fatty acid biosynthesis, amino acid metabolism and gluconeogenesis 62 
where it activates CO2 for the carboxyltransfer domains of the respective enzymes4,5. 63 
Several industrially relevant microorganisms lack the ability to independently synthesize biotin 64 
including Saccharomyces cerevisiae6, Pichia pastoris7 and Corynebacterium glutamicum8,9. In 65 
the case of P. pastoris, for instance, high amounts of the cofactor are added to defined media and 66 
process complications are frequently associated with poor quality of the supplemented biotin7. 67 
Similarly, biotin has to be added in serum-free cell culture medium formulations10. In order to 68 
overcome this limitation, several efforts have been undertaken to genetically engineer 69 
prototrophic variants of different organisms for industrial applications6-9. These works comprised 70 
introduction of biotin biosynthesis genes from naturally prototrophic hosts like Escherichia coli 71 
or Bacillus subtilis. An alternative approach to the aforementioned efforts could be the metabolic 72 
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engineering of biotin-independent organisms that a priori do no longer rely on biotin, which has 73 
thus far not been systematically elaborated. 74 
Biotin metabolism has been extensively studied in E. coli4,5,11,12, where it is used for the 75 
carboxylation of acetyl-CoA to yield malonyl-CoA which represents the first committed step in 76 
fatty acid synthesis13 (Fig. 1). This reaction catalyzed by the acetyl-CoA carboxylase complex 77 
(AccABCD) is the only essential utilization of biotin in E. coli. Other than that, only propionate 78 
metabolism has been reported to rely on biotin for the carboxylation of propionyl-CoA in some 79 
strains but the corresponding genes and gene products remain elusive14. Despite its scarce usage, 80 
the biosynthesis of biotin is a metabolically costly procedure involving many enzymatic steps 81 
(Fig. 1): starting from glucose, a minimum of twelve enzymatic reaction steps is required to yield 82 
acetyl-CoA15, which is then converted into malonyl-CoA by the aforementioned AccABCD 83 
reaction13. Subsequently, the fatty acid synthesis machinery is employed to successively couple 84 
three malonyl-CoA units in ten enzymatic steps to yield pimeloyl-ACP methyl ester4. This 85 
precursor is processed into biotin by five final biosynthesis enzymes (BioHFADB) before 86 
loading the cofactor onto the biotinyl carboxyl carrier protein (BCCP) by the biotin ligase BirA4. 87 
Hence, at least 29 steps are required to produce biotin including the comparably inefficient, yet 88 
catalytic, final biotin synthase (BioB) reaction16,17 and not to mention involved cofactors (SAM, 89 
NAD(P)+/NAD(P)H, CoA, ATP etc.) and the genetics of biotin biosynthesis including 90 
regulation18,19. 91 
In this work we describe the creation of biotin-independent phenotypes by re-wiring initial fatty 92 
acid biosynthesis using a malonyl-CoA bypass. The resulting engineered strains of E. coli and 93 
C. glutamicum are able to survive and proliferate in the complete absence of biotin. We apply 94 
this concept of biotin-independence to improve the production of the high-affinity biotin binder 95 
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streptavidin (SAV hereafter), which was thus far restricted due to toxic biotin depletion in the 96 
host cell. The biotin-independent E. coli strain revealed a significantly enhanced SAV production 97 
as well as improved growth behavior as compared to a conventional strain. Transferring this 98 
strategy to an SAV production process in lab-scale bioreactors and fine-tuning of the bypass led 99 
to the highest streptavidin titers reported to date (up to 8.3±0.2 g L-1). 100 
 101 
 102 
 103 
Fig. 1 | A biotin-independent bypass for malonyl-CoA synthesis. Biotin biosynthesis from glucose requires 29 104 
enzymatic steps including synthesis of acetyl-CoA (orange box) and fatty acids (grey box) as well as the final steps 105 
exclusive to biotin production (green box). AccABCD requires biotin as cofactor for the essential conversion of 106 
acetyl-CoA to malonyl-CoA during fatty acid synthesis in most natural organisms20. Bypassing this reaction creates 107 
a biotin-independent phenotype achieved by implementing two heterologous proteins from R. trifolii (blue box) 108 
facilitating uptake of malonate (MatC) and its subsequent conversion to malonyl-CoA (MatB). The resulting strain 109 
should be superior to conventional hosts in its capability to produce biotin-binders such as streptavidin (SAV; red 110 
box), which is hitherto restricted due to the sequestration of biotin and inhibition of AccABCD21,22. 111 
 112 
 113 
 114 
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2. Materials and methods 118 
2.1 Suppliers 119 
All chemicals were purchased from Sigma Aldrich (Buchs, Switzerland) unless stated otherwise. 120 
Enzymes and reagents for cloning were purchased at New England Biolabs (Ipswich, USA). 121 
Purified, lyophilized SAV was kindly provided by Prof. Thomas R. Ward (University of Basel, 122 
Switzerland). 123 
 124 
2.2 Growth media 125 
E. coli strains were grown in Luria–Bertani (LB) liquid medium or agar23 for maintenance and 126 
genetic engineering supplemented with 50 mg L-1 kanamycin or 34 mg L-1 chloramphenicol 127 
where appropriate. The basic M9 medium23 contained 10 g L-1 glucose and 20 mg L-1 thiamine. 128 
For the experiments with JM83 and its derivatives (Fig. 2(b)-(c); Supplementary Fig. 1; 129 
Supplementary Fig. 3) basic M9 was additionally supplemented with 1 mM L-proline, 500 µM 130 
isopropyl-β-D-thiogalactopyranosid (IPTG) and 50 mg L-1 kanamycin or 34 mg L-1 131 
chloramphenicol where appropriate. Additionally 0.2 mg L-1 D-biotin or between 0 and 50 mM 132 
malonate were added to yield M9BIO+ and M9MAL+, respectively. For SAV expression with 133 
BL21(DE3) in shake flasks (Fig. 3(b)) and for the batch phase of bioreactor cultivations (Fig. 4) 134 
a defined mineral medium (pH 7.0) was used containing 3.0 g L-1 KH2PO4, 4.2 g L-1 Na2HPO4, 135 
2.3 g L-1 (NH4)2SO4, 1.9 g L-1 NH4Cl, 1 g L-1 citric acid, 10 g L-1 glucose, 20 mg L-1 thiamine, 55 136 
mg L-1 CaCl2, 240 mg L-1 MgSO4, 50 mg L-1 kanamycin, 34 mg L-1 chloramphenicol, and 137 
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1 mL L-1 trace element solution US 24. Heterologous gene expression was induced by addition of 138 
500 µM IPTG and where appropriate a concomitant malonate pulse to a final concentration of 5 139 
mM was added. 140 
Glucose feed medium (phase II bioreactor cultivation, Fig. 4(a)) contained 400 g L-1 glucose, 141 
13.3 g L-1 MgSO4 · 7H2O, 20 mg L-1 thiamine, 50 mg L-1 kanamycin, 34 mg L-1 chloramphenicol 142 
and 1 mL L-1 trace element solution US24. Glucose-malonate feed medium (phase III bioreactor 143 
cultivation, Fig. 4(a)) was prepared likewise and additionally contained between 0 and 560 mM 144 
malonate (pH adjusted to 7.0 by addition of sodium hydroxide). 145 
For strain maintenance C. glutamicum was grown in LB liquid medium or agar containing 146 
10 g L-1 glucose and where appropriate 25 mg L-1 kanamycin. Transformation was performed by 147 
electroporation as described elsewhere25. For biotin complementation experiments with 148 
C. glutamicum the minimal medium CGXII26 with 2% glucose (w/v) was used either with 149 
(20 mg L-1) or without biotin or supplemented with varying concentrations of malonate. Unless 150 
stated otherwise 10 µM IPTG were added for induction of matBC genes in this strain. 151 
  152 
2.3 Cultivation conditions 153 
E. coli growth experiments in microtiter plates were carried out in an Infinite M200 plate reader 154 
(Tecan, Männedorf, Switzerland) at 37°C and under agitation (orbital shaking, 2 mm amplitude) 155 
and bacterial growth was monitored by measuring the optical density of the cultures (200 µL 156 
total volume) at 600 nm (OD600). Shake flask cultivations were carried out using 1 L Erlenmeyer 157 
flasks and a culture volume of 100 mL in a shaking incubator (37°C, 220 r.p.m.) and growth was 158 
monitored by OD600 determination in a cuvette photometer. SAV concentrations were 159 
determined by a fluorescence quenching assay (see section 2.7). 160 
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C. glutamicum was cultivated in 96-deepwell plates in 500 µL culture volume. Wells were 161 
inoculated from single colonies from biotin-containing CGXII plates (1.6% agarose) and 162 
cultivation was performed in a shaking incubator (30°C, 250 r.p.m.) for 48 h. The final OD600 163 
was determined in an Infinite M1000 plate reader (Tecan, Männedorf, Switzerland). 164 
 165 
2.4 Bioreactor cultivation 166 
Bioreactor cultivations with E. coli were carried out with a Labfors-5 benchtop fermenter system 167 
(Infors HT, Bottmingen, Switzerland) with 7.5 L vessel volume at 37°C and a pH of 7.0 which 168 
was maintained by titration with 10% (v/v) sulfuric acid and 5 M ammonium hydroxide. The 169 
dissolved oxygen concentration was maintained above 30% of the saturation level by firstly 170 
adjusting the stirrer speed (300 to 1250 rpm, 50 rpm increments; two six-blade Rushton 171 
impellers) and secondly the air flow (1 to 5 vvm).   172 
The batch phase was started by inoculation of 2 L of defined mineral medium to an initial OD600 173 
of 0.15 from an overnight shake flask pre-culture in the same medium. In order to prevent 174 
foaming 1 mL of 20% (v/v) of polypropylene glycol was added to the culture and additionally as 175 
necessary in 500 µL increments throughout the cultivation. After the consumption of the initial 176 
amount of glucose (10 g L-1), as indicated by a sudden rise in the dissolved oxygen signal, 177 
glucose feed medium was gradually applied to the culture in an exponential manner (µset = 178 
0.09 h-1) until an approximate OD600 of 55 was reached (corresponding to a dry cell weight 179 
concentration (DCW) of roughly 21 g L-1). Subsequently, heterologous gene expression was 180 
induced by addition of 500 µM IPTG and the administered medium was switched to glucose-181 
malonate feed medium which was applied at a constant rate of 0.53 mL min-1 until the end of the 182 
process. Cell growth was monitored throughout the process by OD600 determination and DCW 183 
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measurement and SAV concentrations were determined by a fluorescence quenching assay (see 184 
section 2.7). 185 
 186 
2.5 Strain engineering 187 
All strains used in this study are listed in Supplementary Table 1. In order to facilitate 188 
transcription using PT7 promoters, the T7 RNA polymerase was integrated into the chromosome 189 
of strain JM83 using the λDE3 Lysogenization Kit (Merck-Millipore, Darmstadt, Germany) and 190 
the resulting strain was designated JM83(DE3). A biotin auxotroph derivative of JM83(DE3) 191 
was created by P1 transduction from the Keio collection strain BW25113, which carries an 192 
insertional knockout of the biotin synthase gene (bioB:kan), as described elsewhere27. 193 
Subsequently the kanamycin resistance gene was removed using FRT recombination with 194 
plasmid pCP20, which was cured from the resulting strain JM83(DE3)ΔbioB by incubation at 195 
43°C28. Colony PCR was performed to verify both successful transduction and removal of the 196 
resistance gene using primers 1 and 2 flanking the bioB gene (Supplementary Tab. 2). 197 
 198 
2.6 Cloning procedures 199 
All plasmids used in this study are listed in Supplementary 1. The natural matBC cassette from 200 
R. trifolii was obtained as a synthetic DNA fragment (Life Technologies, Regensburg, Germany; 201 
Supplementary Tab. 3) and PCR-amplified using oligonucleotides 3 and 4 in order to introduce 202 
flanking restriction sites for BamHI and EcoRV. Accordingly, the plasmid pCK0129 was PCR-203 
amplified with primers 5 and 6 introducing sites for BamHI and EcoRV. Both PCR products 204 
were digested (BamHI and EcoRV) and joined by ligation resulting in plasmid pCKmatBC. To 205 
generate pET30matBC the synthetic DNA construct of matBC (Supplementary Tab. 3) was PCR 206 
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amplified (primers 7 and 4) and the resulting PCR product was digested and ligated into the 207 
backbone of pET-30b(+) treated with the same restriction enzymes (NdeI and EcoRV). 208 
pET30matBC*, in which the natural GTG start codon of the matB gene is replaced by ATG, was 209 
constructed by digestion of the PCR product of the matBC cassette (Supplementary Tab. 3) and 210 
primers 8 and 9 with NdeI and BamHI and subsequent ligation into the backbone of pET-30b(+) 211 
treated with the same restriction enzymes (NdeI and BamHI). 212 
pEKEx2matBC was constructed by PCR amplification of the natural matBC cassette 213 
(Supplementary Tab. 3) with primers 10 and 11 followed by restriction digest with BamHI and 214 
KpnI and subsequent ligation into the backbone of pEKEx230 treated with the same restriction 215 
enzymes. 216 
 217 
2.7 Quantification of active SAV 218 
Cell lysates of E. coli were produced by spinning down (20’000 rcf, 5 min, 4° C) 1 mL of broth 219 
and re-suspending the cell pellet in lysis buffer (10 mM Tris buffer at pH 7.4 containing 1.0 g L-1 220 
lysozyme, 1 mM MgSO4 and 10 mg L-1 DNAse). Afterwards, three consecutive freeze-thaw 221 
cycles were performed and the SAV-containing supernatant was cleared from cell debris by 222 
centrifugation (20’000 rcf, 10 min, 4° C). Free biotin binding sites in SAV were then quantified 223 
using a fluorescent quenching assay derived from a previously described protocol31. For this 224 
purpose, a binding site buffer containing 1 µM Atto-565-biotin (Atto-Tec, Siegen, Germany) and 225 
0.1 g L-1 bovine serum albumin in phosphate buffered saline 23 was freshly prepared for each 226 
measurement. Aliquots of 10 µL of samples (diluted into the linear range of the assay; 0-0.95 227 
µM biotin-binding sites) were mixed with 190 µL of binding site buffer and incubated for 30 228 
minutes at ambient temperature to ensure binding of the dye to SAV. Afterwards a fluorescent 229 
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measurement was performed (λEx = 563 nm, λEm = 620 nm) in black 96-well microtiter plates 230 
using an Infinite M1000Pro microtiter plate reader (Tecan, Männedorf, Switzerland) and SAV 231 
concentrations were calculated by correlation with an SAV standard curve (prepared from 232 
purified, lyophilized SAV) similarly prepared as the samples and recorded in the same plate. The 233 
cell specific SAV yields were calculated from the measured concentrations of SAV and DCW of 234 
the samples assuming a whole cell protein content of 0.5 g per gram DCW. In order to verify 235 
integrity of the product and confirm the validity of the optical quantification by a second method 236 
SDS-PAGE analysis was performed (Supplementary Fig. 4). Therefore cell lysates from one of 237 
the biotin-independent bioreactor processes (Fig. 4(c)) were run in comparison to a purified, 238 
lyophilized SAV standard corresponding to a concentration of 4 g L-1. 239 
 240 
 241 
 242 
 243 
 244 
 245 
 246 
 247 
 248 
 249 
 250 
 251 
 252 
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3. Results and discussion 255 
3.1 Construction of biotin-independent Escherichia coli strains 256 
We hypothesized that biotin as such and consequently the complicated associated metabolic 257 
machinery (final biotin biosynthesis genes and AccABCD complex) could be rendered 258 
superfluous if a biotin-independent route to malonyl-CoA was established. The resulting strain 259 
should be able to proliferate independently of biotin. 260 
In order to create this biotin-independent bypass (Fig. 1) we selected two heterologous genes 261 
(matBC) from the Rhizobium trifolii malonate utilization operon that are responsible for the 262 
uptake of malonate (matC, malonate transporter) and its subsequent conversion to malonyl-CoA 263 
(matB, malonyl-CoA synthetase)32. Malonic acid is a cheap bulk chemical readily synthesized by 264 
plants but its bulk production mainly relies on chemical synthesis from chloroacetic acid33,34. The 265 
matABC gene cluster has been expressed in E. coli previously to improve polyketide 266 
synthesis32,35. Importantly, James and Cronan elegantly demonstrated that this system can be 267 
used to create deletion mutants for various subunits of the essential acetyl-CoA carboxylase36. 268 
Building up on these previous studies, we anticipated that it should be possible to create a biotin-269 
independent phenotype using matBC and supplementation of growth media with malonate and 270 
thereby insulating fatty acid synthesis from central carbon metabolism. Alternatively, malonate 271 
could also be directly synthesized from glucose as very recently demonstrated in genetically 272 
engineered E. coli37. 273 
We constructed three different matBC expression vectors for E. coli differing in the anticipated 274 
expression levels by using different copy numbers and promoters and varying the start codon 275 
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(wild type GTG vs. ATG) of matB (Fig. 2(a)). To test whether the only biotin-dependent reaction 276 
can be bypassed by MatBC, we constructed a strain with disrupted chromosomal biotin synthase 277 
gene bioB which reportedly prevents biotin production and thus growth in biotin-free medium38. 278 
The resulting strain JM83(DE3)ΔbioB was transformed with the different matBC expression 279 
plasmids and plated on selective M9-agar containing either 0.2 mg L-1 biotin or 5 mM malonate 280 
as well as neither of the two supplements (Fig. 2(b)). Whereas parent strain JM83(DE3) 281 
exhibited normal growth even in biotin absence, the bioB mutants failed to proliferate on biotin-282 
free agar. As expected, supplementation of biotin to the medium restored growth for all 283 
auxotroph mutants. Importantly, malonate was likewise able to restore growth but only in 284 
presence of a matBC expression vector and with notably diverging strain fitness depending on 285 
the anticipated expression level for the bypass proteins. More precisely, pCKmatBC (low copy 286 
number, PLac, GTG start codon for matB) exhibited the best growth behavior as compared to 287 
pET30matBC and pET30matBC*, which led to intermediate and slow growth, respectively. 288 
These results confirmed functionality of the biotin-independent malonyl-CoA bypass and pointed 289 
to a preferable low expression level for the bypass proteins, presumably because too high 290 
expression levels lead to excessive drainage of the cellular coenzyme A pool, highlighting the 291 
significance of expression level optimization for metabolic engineering39-41. 292 
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 293 
Fig. 2 | Engineering of biotin-independent strains of E. coli and C. glutamicum. (a) Three E. coli plasmids for 294 
matBC expression were constructed differing in plasmid copy number (ori’s from pSC101 or pBR322) as well as 295 
transcriptional (PLac vs. PT7 promoter) and translational (GTG vs. ATG start codon of matB) control. (b) The MatBC 296 
bypass restores growth of a biotin auxotrophic mutant (ΔbioB) on biotin-free solid medium containing 5 mM 297 
malonate (M9MAL+) with preference for low expression levels (pCKmatBC). Malonate-free (M9) and biotin-298 
containing (M9BIO+) media were included as negative and positive control, respectively. (c) The malonate 299 
concentration was optimized to ensure optimal growth of biotin-independent E. coli. (d) Construction of a matBC 300 
shuttle vector (pEKEx2matBC) allowed for biotin-independent growth of naturally biotin auxotroph C. glutamicum. 301 
Bars represent average specific growth rates and/or maximum OD600 for three (c) or four (d) replicate cultures in 96-302 
well format with s.d.. 303 
 304 
3.2 Optimization of malonate supply 305 
To quantify growth of the biotin-independent strain and investigate a potential influence of the 306 
amount of supplemented malonate, we conducted cultivations of JM83(DE3)ΔbioB pCKmatBC 307 
in microtiter plates (Fig. 2(c)) and shake flasks (see Supplementary Fig. 1) in biotin-free M9 308 
liquid medium. We found growth to depend on the supplied malonate concentration and 309 
identified an optimum at which the growth rate was restored roughly to the same level as in 310 
presence of biotin which corresponds well with typically observed growth rates for wildtype 311 
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strains in mineral media. Concentrations exceeding the apparent optimum negatively affected the 312 
strains behavior as far as to complete growth inhibition. Similar observations were made by 313 
Lombó and coworkers35 who observed growth of a normal, biotin prototroph strain at 5 mM but 314 
complete inhibition at 40 mM malonate and attributed the inhibitory effect on imbalances in the 315 
host’s coenzyme A and acyl-CoA metabolism. Moreover, malonate is known to inhibit succinate 316 
dehydrogenase, a central enzyme of the Krebs cycle42. Consequently, malonate supply needs to 317 
be optimized for the desired strain and cultivation vessel in order to exploit the full potential of 318 
the malonyl-CoA bypass. 319 
 320 
3.3 Grafting of MatBC bypass to Corynebacterium glutamicum 321 
In order to evaluate transferability for the proposed biotin-independent concept, we selected the 322 
Gram-positive bacterium Corynebacterium glutamicum as a second chassis to demonstrate 323 
functionality of the MatBC bypass. C. glutamicum is an industrially highly relevant production 324 
host43,44 and naturally biotin auxotrophic therefore requiring supplementation of defined media 325 
with the vitamin9. This latter practical limitation has been previously addressed by re-326 
introduction of biotin biosynthesis genes into C. glutamicum to create biotin-prototrophic 327 
phenotypes8,9. Besides the essential acetyl-CoA carboxylase, C. glutamicum contains a biotin-328 
dependent pyruvate carboxylase, which is responsible for anaplerotic channeling of pyruvate into 329 
the tricarboxylic acid cycle45. Complementation studies, however, revealed that pyruvate 330 
carboxylase is inessential and the corresponding deficient mutants exhibit wild type growth45. 331 
We therefore hypothesized that the MatBC-bypass would likewise render biotin obsolete in 332 
C. glutamicum creating mutants proficient to grow in biotin-free medium supplemented with 333 
malonate. We constructed the vector pEKEx2matBC with the natural matBC cassette under 334 
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control of a Ptac promoter. Gratifyingly, transformation of C. glutamicum wild type (ATCC 335 
13032) with this construct enabled its proliferation in biotin-free media containing malonate 336 
whereas in the absence of MatBC (pEKEx2) as well as in medium lacking malonate only 337 
marginal growth due to residual biotin transferred from the pre-cultures was observable 338 
(Fig. 2(d)). Moreover, we found a strong growth inhibition for high inducer concentrations 339 
pointing to a similar preference for low matBC expression levels as previously observed for 340 
E. coli (see Supplementary Fig. 2). Taken together these experiments highlight the feasibility to 341 
create biotin-independent organisms using the MatBC bypass and the transferability of the 342 
underlying concept to different hosts. 343 
 344 
3.4 Utilization of biotin-independence for cytosolic streptavidin production 345 
Next, we sought to demonstrate practical utility of biotin independence and apply a respective 346 
E. coli strain to address a common problem occurring during expression of high-affinity biotin 347 
binders like streptavidin (SAV). Due to the high affinity to biotin (SAV, KD, biotin ~10-14 M) and 348 
its exceptional physicochemical stability, SAV is used for a multitude of biotechnological 349 
applications including live cell imaging, immobilization and affinity purification of biotinylated 350 
or peptide tagged biomolecules and nanotechnology as well as more recently developed 351 
technologies which repurpose the protein for drug targeting and the development of artificial 352 
metalloenzymes46-48. The secretion of SAV and its homologues by natural hosts such as 353 
Streptomyces avidinii serves as defense mechanism exploiting the highly efficient sequestration 354 
of the vitamin21,49. Not coincidentally, the expression of soluble, active SAV in the cytosol has 355 
been reported to lead to depletion of the host cell’s biotin pool accompanied by impaired growth 356 
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and low SAV expression levels21,22,50, which represents a major limitation for high-yield SAV 357 
production. 358 
We presumed that the capability to bypass the critical biotin-sensitive metabolic step should lead 359 
to superior behavior in SAV expression without the accompanying negative effects and should 360 
therefore be of use for a corresponding SAV production strategy. We therefore introduced a 361 
second plasmid (pET30T7SAV) with the SAV gene under the control of a PT7 promoter into a 362 
strain harboring pCKmatBC (Fig. 3(a)). As production host we selected the strain E. coli 363 
BL21(DE3) since it is conventionally used for high biomass production and protein expression. 364 
Since BL21(DE3) is a biotin prototrophic strain, in the absence of SAV (before induction) the 365 
malonyl-CoA bypass is not needed, but its expression from pCKmatBC can be concomitantly 366 
activated with SAV induction from pET30T7SAV by addition of IPTG. This “switchable” 367 
MatBC bypass allows for normal growth in the off-state without the need to supplement 368 
malonate before induction, which is an important practical advantage. At the same time it should 369 
facilitate improved growth and production behavior in the on-state after induction of SAV.    370 
To validate this hypothesis we conducted SAV expression studies in shake flasks in M9 medium, 371 
both with and without 5 mM malonate supplementation and in the absence (matBC-, empty 372 
vector control) or presence of pCKmatBC (matBC+, Fig. 3(b)). As expected, all four specimens 373 
showed very similar growth in the off-state until addition of IPTG (dashed line). Afterwards, the 374 
conditionally biotin-independent strain showed a significantly improved growth behavior only in 375 
presence of malonate (matBC+ MAL+) as compared to the conventional strain (matBC-, MAL+/-) 376 
and the control lacking malonate (matBC+ MAL-). More importantly, SAV expression was 377 
notably improved in the biotin-independent strain as reflected by a roughly two-fold increased 378 
final concentration. We performed similar experiments with strain JM83(DE3) revealing similar 379 
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trends and a more than three-fold increase in SAV production (see Supplementary Fig. 3). These 380 
results unambiguously demonstrate the functionality of the biotin-independent bypass and its 381 
utility for improved expression of SAV. 382 
 383 
 384 
Fig. 3 | Streptavidin (SAV) production in conditionally biotin-independent E. coli strains. (a) For production of 385 
SAV in E. coli the vector pET30T7SAV was constructed. It contains the SAV gene under control of a PT7 promoter. 386 
(b) Shake flask cultivations with E. coli BL21(DE3) revealed significantly improved growth and SAV production 387 
behavior after SAV induction in the biotin-independent strain in presence of 5 mM malonate (matBC+ MAL+) 388 
compared to the controls lacking either pCKmatBC (matBC- MAL+ and matBC- MAL-) or malonate (matBC+ 389 
MAL-). Data points represent mean OD600 and SAV concentrations of three independent cultures with standard 390 
deviation. 391 
 392 
3.5 Establishment of a biotin-independent streptavidin production process 393 
Next, we transferred the switchable biotin-independent SAV production into a laboratory scale 394 
bioreactor process using defined medium. Therefore we developed a cultivation protocol 395 
composed of three conceptual stages (Fig. 4(a)): an initial batch phase (I), a fed-batch stage (II) 396 
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with exponential glucose-limited feeding (biomass production), and an SAV production stage 397 
(III) initiated by induction with IPTG, during which a mixture of malonate and glucose is applied 398 
in a constant manner throughout the rest of the process. Since the initial studies had pointed to a 399 
critical requirement of a fine-tuned malonate supply depending on the cultivation conditions, we 400 
investigated the effect of different malonate-to-glucose ratios in the feed medium during SAV 401 
production (III) (Fig. 4(b)). The strain lacking matBC reproducibly yielded similar amounts of 402 
SAV (~4 g L-1) regardless of the malonate amount fed to the broth. In stark contrast the biotin-403 
independent strain (matBC+) showed a production behavior depending on the applied malonate 404 
amount with a peak concentration of 7.3±0.2 g L-1 SAV at 0.56 mmol malonate per gram of 405 
glucose. To demonstrate reproducibility we performed replicate bioreactor runs at the identified 406 
malonate optimum (Fig. 4(c)). The biotin-independent strain outperformed the conventional 407 
strain both with respect to growth and SAV production and allowed for a reproducibly higher 408 
maximum product concentration of 7.5±0.7 g L-1 of active SAV (compared to 4.7±0.2 g L-1). The 409 
best run yielded 8.3±0.2 g L-1 (or 126.3±3.0 µM tetramer) of product (compare also 410 
Supplementary Fig. 4). This improvement can be attributed both to an improved growth after 411 
induction of SAV expression as well as to an increased cell specific product yield of 412 
approximately 49±4% of whole cell protein (as compared to 38±1% for the control) indicating 413 
that the re-programmed strain’s performance was driven close to the reported feasible maximum 414 
for recombinant protein expression in E. coli51.  415 
To the best of our knowledge the titers produced with the biotin-independent strain represent the 416 
highest SAV concentrations reported to date and constitute a significant increase compared to 417 
former benchmark studies52,53. Moreover, due to the high specific growth rate of E. coli, which 418 
allows comparably short overall process times, the volumetric productivity was substantially 419 
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increased in comparison to previously used hosts for SAV production such as S. avidinii, P. 420 
pastoris, or B. subtilis 52-54. 421 
 422 
 423 
Fig. 4 | Development of a streptavidin (SAV) production process in biotin-independent E. coli. (a) A three-424 
stage bioreactor process was developed: I, batch phase; II, exponential glucose-limited fed-batch; III, SAV 425 
production phase with constant glucose-malonate feed. The idealized courses for concentration of biomass X and 426 
SAV and the volumetric feed flow rate 𝐹!" are conceptually shown. (b) The critical malonate-glucose ratio in the 427 
feed (phase III) was optimized. Maximum SAV concentrations eight hours after induction are indicated. (c) The 428 
productivity of the optimal setup (0.56 mmol gGlc-1) was verified by three independent bioreactor cultivations of the 429 
biotin-independent strain (blue squares/circles) compared to two independent reference cultivations with the 430 
conventional strain (matBC-) without malonate (grey squares/circles). Bars/data points represent averages of 431 
triplicate measurements of dry cell weight (DCW) and SAV concentration with standard error. The area between the 432 
dashed lines represents the IPTG induction window of all five processes. SDS-PAGE analysis for the biotin-433 
independent process was performed to confirm integrity of the product (see Supplementary Fig. 4) 434 
 435 
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4. Conclusion 436 
Metabolic engineering is widely used to improve bioprocess performance by directing fluxes into 437 
a desired product based on the ever increasing knowledge about cellular metabolic networks55. 438 
Well established strategies include overexpression or deletion of inherent host enzymes to 439 
increase the flux into the target pathway or prevent drainage of intermediates and consequently 440 
product loss or side product formation, the integration of enzymes facilitating growth and 441 
product formation based on inexpensive substrates, as well as implementation of proteins which 442 
simplify downstream processing. These efforts are frequently combined with flux models that 443 
help identifying the key bottlenecks within the system 56,57. 444 
A relatively uncharted approach is the fundamental re-organization of central host metabolism in 445 
order to enhance bio-production. This strategy seeks to completely re-route central metabolic 446 
pathways in order to drive their flux into a desired direction and is based on the notion that 447 
natural metabolism, as good as it is to cope with natural challenges, may not be the preferable 448 
choice for biotechnological application. Auspicious examples comprise a synthetic non-oxidative 449 
glycolysis58 and a reverse glyoxylate shunt59, both designed to minimize carbon loss upon 450 
utilization of carbohydrates, as well as the engineering of artificial carbon fixation cycles with 451 
the goal to increase sequestration of the greenhouse gas carbon dioxide60-63. Despite the fact that 452 
some of these efforts thus far mainly comprised theoretical considerations and in vitro studies 453 
and have therefore hardly exceeded the stage of a blueprint, this type of approach could arguably 454 
enable to fundamentally change cellular metabolism as we know it today and may allow 455 
accessibility to entirely novel processes and bio-products. 456 
In this work we re-route the central pathway of fatty acid biosynthesis by installation of a bypass 457 
for malonyl-CoA to liberate the corresponding strains of E. coli and C. glutamicum from their 458 
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dependence on biotin, an essential vitamin evolutionary conserved in all kingdoms of life. The 459 
engineered organisms exhibit normal growth in the absence of the cofactor and can be used for 460 
biotechnological applications as demonstrated on the test bed of SAV production, which was 461 
previously restricted due to toxic biotin depletion in the host cell21,22,50. This led to the 462 
establishment of an SAV production process with hitherto unmatched maximum titers and 463 
productivities. 464 
To extend the biotin-independent concept beyond this proof-of-principle study, the entire cellular 465 
machinery associated with biotin could be removed from the host genome. This includes genes 466 
involved in its biosynthesis (bioHFADB), its loading (birA), as well as all acetyl-CoA 467 
carboxylase genes (accABCD). Furthermore, the presented MatBC bypass could be combined 468 
with a module for in vivo synthesis of malonate, which has recently been established in an 469 
engineered E. coli strain that is capable of synthesizing malonate from aspartate via a beta-470 
alanine route37. This would close the gap to prevalent metabolites that can be directly derived 471 
from central metabolism and render the currently required (yet inexpensive) supplementation of 472 
malonate obsolete, leading to a stand-alone biotin-independent organism, which synthesizes fatty 473 
acid building-blocks in a completely novel way. 474 
We believe that this work represents a prime example indicating that even fundamental design 475 
principles of cellular carbon flux in living cells can be simplified for synthetic purposes. This 476 
suggests a hitherto largely unappreciated malleability of core metabolism, which augurs well for 477 
future fundamental re-design of bacterial metabolism using abiotic reactions48,64. 478 
 479 
 480 
 481 
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